Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis

被引:9
|
作者
Kelly, Bridget N. [1 ]
Webster, Alexandra J. [1 ]
Lamb, Leslie [2 ]
Spivey, Tara [1 ]
Korotkin, Jenna E. [1 ]
Henriquez, Anthony [1 ]
Gadd, Michele A. [1 ]
Hughes, Kevin S. [1 ]
Lehman, Constance R. [2 ]
Smith, Barbara L. [1 ]
Specht, Michelle C. [1 ]
机构
[1] Massachusetts Gen Hosp, Div Surg Oncol, Yawkey 7,55 Fruit St, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Radiol, Boston, MA 02114 USA
关键词
Breast conserving surgery; Magnetic seed localization; Wireless localization; Lumpectomy; Preoperative; identification (RFID) seeds; nonradioactive radar localization (SAVI; ONCOLOGY CONSENSUS GUIDELINE; CONSERVING SURGERY; AMERICAN SOCIETY; LOCALIZATION; IRRADIATION; MARGINS; LESIONS; SYSTEM;
D O I
10.1016/j.clbc.2022.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Magnetic seed is an alternative to wires for localization of nonpalpable breast lesions that uses a wireless detector probe to guide the surgeon to an implanted magnetic seed. Operative time, specimen volume, postoperative opioid administration, and re-excision rate were compared between the 2 cohorts. We found magnetic seeds to be a feasible alternative to wires with regard to surgical outcomes. Introduction: Magnetic seeds have emerged as an alternative to wires for localization of nonpalpable breast lesions. The purpose of this study was to evaluate the utility of magnetic seeds compared to wires for preoperative localization. Materials and Methods: A retrospective cohort analysis of magnetic seed localization (MSL) and wire localization (WL) excisional biopsies and lumpectomies performed at a single institution was conducted. Indication, age, BMI, number of markers, procedure type, operative time, and postoperative opioid administration were reviewed. Impact of localization method on operative time, specimen volume, postoperative opioid administration, and re-excision rate were assessed. Results: A total of 608 MSL procedures in 601 patients were compared to 628 WL procedures in 620 patients. MSL excisional biopsies were significantly longer (37.0 minutes) than WL excisional biopsies (31.9 minutes, P < .001), but in lumpectomies without axillar y surger y, MSL procedures (42.3 minutes) were significantly shorter than WL procedures (46.9 minutes, P = .017). Significantly less tissue was excised during MSL lumpectomies (68.5 cm 3 ) and excisional biopsies (32.3 cm 3 ) than WL lumpectomies (78.1 cm 3 , P = .039) and excisional biopsies (38.7 cm 3 , P = .018). Postoperative opioid administration was similar for MSL and WL procedures ( P = .076). Re-excision rates for MSL lumpectomies were significantly higher for ductal carcinoma in situ (35.3% MSL vs. 18.5% WL, P = .013), but were similar for invasive carcinoma (14.4% MSL vs. 17.7% WL, P = .290). Logistic regression analysis showed no association between localization method and re-excision (OR 1.007, 95% CI 0.681-1.488; P = .973). Conclusion: MSL is a feasible alternative to WL for excision of nonpalpable breast lesions with regard to surgical outcomes.
引用
收藏
页码:E700 / E707
页数:8
相关论文
共 50 条
  • [41] Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
    Hashemi-Meshkini, Amir
    Keshavarz, Khosro
    Gharibnaseri, Zahra
    Kheirandish, Mehrnaz
    Kebriaeezadeh, Abbas
    Nikfar, Shekoufeh
    Abdollahi, Mohammad
    ARCHIVES OF MEDICAL SCIENCE, 2013, 9 (03) : 472 - 478
  • [42] Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer
    Claessens, Anouk K. M.
    Busschbach, Jan J. V.
    Ramaekers, Bram L. T.
    Erdkamp, Frans L. G.
    Bouma, Jeanette M.
    van Leeuwen-Stok, A. Elise
    Tjan-Heijnen, Vivianne C. G.
    Bos, Monique E. M. M.
    ACTA ONCOLOGICA, 2022, 61 (05) : 619 - 624
  • [43] A COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB EMTANSINE IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE UNRESECTABLE OR METASTATIC BREAST CANCER IN PORTUGAL
    Andrade, A.
    Sousa, R.
    Silva, Almeida E.
    Macedo, B.
    Tavares, A. L.
    VALUE IN HEALTH, 2024, 27 (12) : S90 - S91
  • [44] Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma
    Hillner, BE
    Radice, D
    CANCER, 2001, 91 (03) : 484 - 489
  • [45] COST-EFFECTIVENESS OF ADJUVANT TRASTUZUMAB FOR EARLY BREAST CANCER IN ASIA: A SYSTEMATIC REVIEW
    Rafar, Abdul N. R.
    Neoh, C. F.
    Othman, M. F.
    Hong, Y. H.
    VALUE IN HEALTH, 2018, 21 : S14 - S14
  • [46] COMPARATIVE STUDY OF THE COST-EFFECTIVENESS OF TRASTUZUMAB IN THE TREATMENT OF BREAST CANCER IN DIFFERENT COUNTRIES
    Rabbani, S.
    Ardam, A.
    Salamzadeh, J.
    VALUE IN HEALTH, 2013, 16 (07) : A411 - A411
  • [47] Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review
    Chan, Agnes L. F.
    Leung, Henry W. C.
    Lu, Chin-Li
    Lin, Shun Jin
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (02) : 296 - 303
  • [48] Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?
    Garattini, Livio
    van de Vooren, Katelijne
    Curto, Alessandro
    HEALTH POLICY, 2015, 119 (02) : 212 - 216
  • [49] A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
    Sun, Li
    Brentnall, Adam
    Patel, Shreeya
    Buist, Diana S. M.
    Bowles, Erin J. A.
    Evans, D. Gareth R.
    Eccles, Diana
    Hopper, John
    Li, Shuai
    Southey, Melissa
    Duffy, Stephen
    Cuzick, Jack
    dos Santos Silva, Isabel
    Miners, Alec
    Sadique, Zia
    Yang, Li
    Legood, Rosa
    Manchanda, Ranjit
    JAMA ONCOLOGY, 2019, 5 (12) : 1718 - 1730
  • [50] Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA
    Jingyan Wang
    Yinzhi Yi
    Xiaomin Wan
    Xiaohui Zeng
    Ye Peng
    Chongqing Tan
    Advances in Therapy, 2022, 39 : 4583 - 4593